05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
04:00 , Oct 28, 2017 |  BioCentury  |  Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
20:31 , Feb 3, 2017 |  BioCentury  |  Strategy

Delineating IL-2

While Celgene Corp. has a history of entering creative deals that enable its smaller partners to retain control over early development, Delinia Inc.’s clinically validated approach to treating autoimmune diseases, paired with preclinical proof-of-concept data,...